Join the waitlist to be notified when it launches
Antioxidants 10 , 1175 (2021)
Even when plans cover GLP-1 drugs, they typically require: The administrative burden is substantial
Hawaii 5% Full List of GLP-1 Map State-by-State | Alphabetical Order Alabama Number of Prescriptions (2024) : 993,406 Increase from 2023: 0.4% Statewide GLP-1 Usage: 19% Alaska Number of Prescriptions (2024) : 128,658 Increase from 2023: 21.8% Statewide GLP-1 Usage: 17% Arizona Number of Prescriptions (2024) : 614,174 Increase from 2023: 12.6% Statewide GLP-1 Usage: 8% Arkansas Number of Prescriptions (2024) : 535,706 Increase from 2023: -1.4% Statewide GLP-1 Usage: 17% California Number of Prescriptions (2024) : 3,731,277 Increase from 2023: 5.4% Statewide GLP-1 Usage: 9.5% Colorado Number of Prescriptions (2024) : 464,404 Increase from 2023: 17.2% Statewide GLP-1 Usage: 8% Connecticut Number of Prescriptions (2024) : 482,518 Increase from 2023: 12.7% Statewide GLP-1 Usage: 13% Delaware Number of Prescriptions (2024) : 114,101 Increase from 2023: 4.7% Statewide GLP-1 Usage: 11% District of Columbia (Washington D.C.) Number of Prescriptions (2024) : DATA NOT PROVIDED Increase from 2023: DATA NOT PROVIDED Statewide GLP-1 Usage: DATA NOT PROVIDED Florida Number of Prescriptions (2024) : 2,428,469 Increase from 2023: 23.7% Statewide GLP-1 Usage: 10% Georgia Number of Prescriptions (2024) : 1,705,031 Increase from 2023: 11.1% Statewide GLP-1 Usage: 15% Hawaii Number of Prescriptions (2024) : 73,037 Increase from 2023: 21% Statewide GLP-1 Usage: 5% Idaho Number of Prescriptions (2024) : 289,031 Increase from 2023: -11% Statewide GLP-1 Usage: 14% Illinois Number of Prescriptions (2024) : 1,638,601 Increase from 2023: 13.8% Statewide GLP-1 Usage: 13% Indiana Number of Prescriptions (2024) : 879,327 Increase from 2023: 0.8% Statewide GLP-1 Usage: 13% Iowa Number of Prescriptions (2024) : 527,261 Increase from 2023: 14.4% Statewide GLP-1 Usage: 16.5% Kansas Number of Prescriptions (2024) : 455,116 Increase from 2023: 7.4% Statewide GLP-1 Usage: 15% Kentucky Number of Prescriptions (2024) : 1,009,621 Increase from 2023: 2.6% Statewide GLP-1 Usage: 22% Louisiana Number of Prescriptions (2024) : 932,534 Increase from 2023: -11.6% Statewide GLP-1 Usage: 20% Maine Number of Prescriptions (2024) : 178,725 Increase from 2023: 27.2% Statewide GLP-1 Usage: 13% Maryland Number of Prescriptions (2024) : 604,082 Increase from 2023: 22.6% Statewide GLP-1 Usage: 10% Massachusetts Number of Prescriptions (2024) : 777,322 Increase from 2023: 48% Statewide GLP-1 Usage: 11% Michigan Number of Prescriptions (2024) : 1,600,221 Increase from 2023: 5.4% Statewide GLP-1 Usage: 16% Minnesota Number of Prescriptions (2024) : 622,770 Increase from 2023: 13% Statewide GLP-1 Usage: 11% Mississippi Number of Prescriptions (2024) : 551,702 Increase from 2023: 2% Statewide GLP-1 Usage: 19% Missouri Number of Prescriptions (2024) : 872,356 Increase from 2023: 7.2% Statewide GLP-1 Usage: 14% Montana Number of Prescriptions (2024) : 126,175 Increase from 2023: 7.3% Statewide GLP-1 Usage: 11.5% Nebraska Number of Prescriptions (2024) : 271,949 Increase from 2023: 9% Statewide GLP-1 Usage: 14% Nevada Number of Prescriptions (2024) : 242,809 Increase from 2023: 5.1% Statewide GLP-1 Usage: 8% New Hampshire Number of Prescriptions (2024) : 158,953 Increase from 2023: 15.3% Statewide GLP-1 Usage: 11% New Jersey Number of Prescriptions (2024) : 1,334,806 Increase from 2023: 35.8% Statewide GLP-1 Usage: 14% New Mexico Number of Prescriptions (2024) : 260,260 Increase from 2023: 20.4% Statewide GLP-1 Usage: 12% New York Number of Prescriptions (2024) : 2,820,519 Increase from 2023: 15.1% Statewide GLP-1 Usage: 14% North Carolina Number of Prescriptions (2024) : 1,362,471 Increase from 2023: 5.7% Statewide GLP-1 Usage: 13% North Dakota Number of Prescriptions (2024) : 142,108 Increase from 2023: 20.8% Statewide GLP-1 Usage: 18% Ohio Number of Prescriptions (2024) : 1,694,075 Increase from 2023: 6.9% Statewide GLP-1 Usage: 14.5% Oklahoma Number of Prescriptions (2024) : 798,802 Increase from 2023: 16.8% Statewide GLP-1 Usage: 20% Oregon Number of Prescriptions (2024) : 338,387 Increase from 2023: 12.6% Statewide GLP-1 Usage: 8% Pennsylvania Number of Prescriptions (2024) : 2,240,537 Increase from 2023: 8.8% Statewide GLP-1 Usage: 17% Rhode Island Number of Prescriptions (2024) : 83,436 Increase from 2023: 67.8% Statewide GLP-1 Usage: 7.5% South Carolina Number of Prescriptions (2024) : 745,836 Increase from 2023: 9.3% Statewide GLP-1 Usage: 13.5% South Dakota Number of Prescriptions (2024) : 100,533 Increase from 2023: -11.1% Statewide GLP-1 Usage: 11% Tennessee Number of Prescriptions (2024) : 1,076,487 Increase from 2023: 4.2% Statewide GLP-1 Usage: 15% Texas Number of Prescriptions (2024) : 4,664,860 Increase from 2023: 4.8% Statewide GLP-1 Usage: 15% Utah Number of Prescriptions (2024) : 299,074 Increase from 2023: 6.2% Statewide GLP-1 Usage: 8% Vermont Number of Prescriptions (2024) : 74,681 Increase from 2023: -1.7% Statewide GLP-1 Usage: 12% Virginia Number of Prescriptions (2024) : 1,029,811 Increase from 2023: 9% Statewide GLP-1 Usage: 12% Washington Number of Prescriptions (2024) : 717,454 Increase from 2023: 8.4% Statewide GLP-1 Usage: 9% West Virginia Number of Prescriptions (2024) : 428,637 Increase from 2023: -3.2% Statewide GLP-1 Usage: 24% Wisconsin Number of Prescriptions (2024) : 594,805 Increase from 2023: 21.8% Statewide GLP-1 Usage: 10% Wyoming Number of Prescriptions (2024) : 71,942 Increase from 2023: 17.1% Statewide GLP-1 Usage: 12% How Much Will the GLP-1 Map Change in 2025
DeBoever, C
Current clinical evidence from a meta-analysis of phase 2 and three studies of tirzepatide in participants with T2D indicates that tirzepatide treatment is not associated with an increased risk of MACE-4, a composite outcome comprising the four outcomes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization due to unstable angina (HR = 0.80
